Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMGYXR)

• Drug Name: Dizocilpine Drug Info
• Synonyms: DIZOCILPINE; 77086-21-6; MK-801 (Dizocilpine); UNII-7PY8KH681I; MK-801; Lopac-M-108; Lopac-M-107; MK 801; Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; Dizocilpine [INN]; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; Dizocilpinum; Dizocilpina; MK801; MK-801(Dizocilpine); HSDB 7641; (+)MK-801; (+)-MK-801; (+/-)-MK801; Prestwick2_000109; Prestwick3_000109; Prestwick1_000109; Biomol-NT_000210; SCHEMBL34528; Lopac0_000872; BSPBio_000098; SPBio_002037

Indication

Disease Entry	ICD 11	Status	REF
Cerebrovascular ischaemia	8B1Z	Terminated	[1] , [2]

• Cross-matching ID:
  PubChem CID: 180081
  ChEBI ID: CHEBI:34725
  CAS Number: CAS 77086-21-6
  TTD Drug ID: DMMGYXR
  VARIDT Drug ID: DR00506

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2A (NMDAR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glycine	DMIOZ29	Malnutrition	5B50-5B71	Approved	[5]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[6]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[7]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[8]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[9]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[10]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[11]
L-698532	DMO9HM7	Neurological disorder	6B60	Terminated	[12]
L-695902	DMT1DNS	N. A.	N. A.	Terminated	[10]
L-701324	DMAIJSX	Cerebrovascular ischaemia	8B1Z	Terminated	[12]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[13]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[14]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[15]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[16]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[17]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[3]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[18]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[16]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[16]
Methylthioadenosine	DMC8J6F	Multiple sclerosis	8A40	Terminated	[19]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 1 (NMDAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[20]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[21]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[22]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[6]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[7]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[8]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[23]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[10]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[11]
L-698532	DMO9HM7	Neurological disorder	6B60	Terminated	[12]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2B (NMDAR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[24]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[22]
CP-101,606	DMIU19E	Parkinson disease	8A00.0	Phase 2	[25]
CERC-301	DMSABRI	Major depressive disorder	6A70.3	Phase 2	[26]
RGH-896	DMCHZAN	Peripheral neuropathy	8C0Z	Phase 2	[27]
MIJ821	DMN45RI	Major depressive disorder	6A70.3	Phase 2	[28]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[6]
Neu-2000	DMNJTLC	Cardiac arrest	MC82	Phase 1	[29]
EVT100	DMAKWQD	Major depressive disorder	6A70.3	Phase 1	[30]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[3]
Glutamate receptor ionotropic NMDA 1 (NMDAR1)	TTLD29N	NMDZ1_HUMAN	Inhibitor	[4]
Glutamate receptor ionotropic NMDA 2A (NMDAR2A)	TTKJEMQ	NMDE1_HUMAN	Inhibitor	[4]
Glutamate receptor ionotropic NMDA 2B (NMDAR2B)	TTN9D8E	NMDE2_HUMAN	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2403).
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000713)
• [3] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [4] Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
• [5] Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
• [6] Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
• [7] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [8] Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
• [10] Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
• [11] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [12] Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
• [13] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [14] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [15] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [16] 2011 Pipeline of Can-Fite BioPharm.
• [17] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [18] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [19] Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
• [20] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [21] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [22] 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
• [24] NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
• [25] NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
• [26] Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
• [27] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [28] Clinical pipeline report, company report or official report of Cadent Therapeutics.
• [29] Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
• [30] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)